Capricor Therapeutics (CAPR) Cash from Financing Activities (2010 - 2026)

Capricor Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 2820.64% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $250.3 million, a 66.29% increase from a year earlier, with the FY2025 full-year figure at $248.9 million, up 62.92% from the prior year.
• Cash from Financing Activities retreated to $1.5 million in Q1 2026 per CAPR's latest filing, from $248.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $248.8 million in Q4 2025 and bottomed at $3895.0 in Q1 2023.
• The 5-year median for Cash from Financing Activities is $1.9 million (2022), against an average of $25.5 million.
• Across the five-year window, Cash from Financing Activities jumped 58699.59% in 2024 and slumped 99.99% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $2.9 million in 2022, then jumped by 685.45% to $23.2 million in 2023, then soared by 250.01% to $81.1 million in 2024, then soared by 206.85% to $248.8 million in 2025, then plunged by 99.41% to $1.5 million in 2026.
• Per Business Quant, the three latest CAPR Cash from Financing Activities figures stand at $1.5 million (Q1 2026), $248.8 million (Q4 2025), and $6950.0 (Q3 2025).